Health Care, and more specifically oncology, will continue to gain attention with the events on the calendar this week.
The Sachs 20th Annual Biotech in Europe Forum runs from Monday to Thursday.
Monday, morning, Amgen (NASDAQ:AMGN) will present results from a Phase 1 Study of AMG 160 for prostate cancer as part of the European Society of Medical Oncology Virtual Congress.
And Tuesday morning, Merck, whose oncology division has outperformed competitors over the last few years, is hosting an Oncology Virtual IR Briefing as part of ESMO 2020, according to Seeking Alpha’s Catalyst Watch.
A wave of deals in the cancer-treatment space has sparked sharp rallies across biotech.
The big trigger last week was Gilead Sciences (NASDAQ:GILD) agreeing to acquire Immunomedics (NASDAQ:IMMU) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, used to treat certain forms of breast cancer and being evaluated for a number of other cancers.
On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment. Those companies have assets that are “largely de-risked and target high value indications”, Piper Sandler said.
On the list: Allogene Therapeutics (NASDAQ:ALLO), ALX Oncology (NASDAQ:ALXO), Aptose Biosciences (NASDAQ:APTO), Blueprint Medicines (NASDAQ:BPMC), Clovis (NASDAQ:CLVS), Deciphera (NASDAQ:DCPH), Fate Therapeutics (NASDAQ:FATE), IGM Biosciences (NASDAQ:IGMS), ImmunoGen (NASDAQ:IMGN), Incyte (NASDAQ:INCY), Iovance Biotherapeutics (NASDAQ:IOVA), iTeos Therapeutics (NASDAQ:ITOS), Kura Oncology (NASDAQ:KURA), Mirati Therapeutics (NASDAQ:MRTX), Seattle Genetics (NASDAQ:SGEN), Sutro Biopharma (NASDAQ:STRO), Syros Pharmaceuticals (NASDAQ:SYRS), TCR2 Therapeutics (NASDAQ:TCRR) and Xencor (NASDAQ:XNCR).
The Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) jumped 11.2% last week, compared with a decline of less than 1% in the broader market and rise of less than 1% in the health care sector. It ended the week at $29.08, a new all-time closing high, as it surged past the previous high set in late July.
CNCR is now up 17.4% from its recent low set a mere two weeks ago when it troughed around May levels.
https://seekingalpha.com/news/3615543-sector-watch-oncology-events-cancer-etf-breaks-out
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.